| abstract |
This invention relates to compounds of formula (I) or their pharmaceutically acceptable acid addition salts, in which: (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, alkyl de (C1-C6), halo, CF3, OH or OR7 and R5 is methyl or ethyl; or (b) R2 and R5 are taken together, forming a chroman-4-ol ring; R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; and R6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo (3.2.1) octanyl derivative; except that (a) when R2 and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and b) when R2 and R5 are taken together, at least one of R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; and R6 is a substituted piperidinyl, pyrrolidinyl or 8-azabicyclo (3.2.1) octanyl derivative; except that (a) when R2, R and R5 are taken separately, at least one of R1, R2, R3 and R4 is not hydrogen; and (b) when R1 and R5 are taken together, at least one of R1, R3 and R4 is not hydrogen; its pharmaceutical compositions, and treatment procedures for mammals suffering from sudden attack, spinal cord trauma, traumatic brain injury, multiple infarct dementia, CNS degenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer type, Huntington's disease , Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, pain, AIDS dementia; psychotic states, drug addition, migraine, hypoglycemia, anxiolytic states, urinary incontinence and an ischemic event resulting from CNS surgery, open heart surgery or any procedure during the function of the cardiovascular system is compromised, with a compound of the formula (I ) above or one of its pharmaceutically acceptable salts. |